Cesson-Sévigné
Cesson-Sévigné
Cesson-Sévigné, France13 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Azacitidine Combined With Venetoclax in Patients With Higher-risk Chronic Myelomonocytic Leukemia (AVENHIR) | Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Myeloproliferative Disorders, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, bone marrow disorder, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Active, not recruiting | Phase 2 | 2026-09-29 | NCT05768711 | |
| Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESA | Hemic and Lymphatic Diseases, bone marrow disorder, hematologic disorder, myelodysplastic syndrome | Recruiting | Phase 1 / Phase 2 | 2026-09-29 | NCT05181735 | |
| National Acalabrutinib Observational Study | B-cell chronic lymphocytic leukemia, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, B-Cell, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Not stated | 2026-08-26 | NCT05437250 | |
| Evaluation of the Efficacy of E2R Hypnotherapy in the Management of Chronic Insomnia in Primary Care (HypERR) | Chronic Insomnia, Dyssomnias, Sleep Disorders, Intrinsic, insomnia, nervous system disorder, psychiatric disorder, sleep-wake disorder | Recruiting | Not applicable | 2026-08-19 | NCT06898099 | |
| Oral Azacitidine Combined With Venetoclax in Previously Untreated Higher-risk Myelodysplastic Syndromes | Untreated Myelodysplastic Syndrome | Active, not recruiting | Phase 1 / Phase 2 | 2026-08-11 | NCT05782127 | |
| Asciminib Prospective Non Interventional Study as 3rd Line Therapy or More to Treat Adult Patients With CML- CP in Real World Setting in France | Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Myeloproliferative Disorders, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, bone marrow disorder, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Active, not recruiting | Not stated | 2026-05-29 | NCT06092879 | |
| AFU Registry of the Therapeutic Management and Follow-up of Non-Muscle-Invasive Bladder Cancer | Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Non-Muscle Invasive Bladder Neoplasms, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, Urogenital Diseases, Urogenital Neoplasms, benign urinary system neoplasm, carcinoma, epithelial neoplasm, neoplasm, urinary bladder disorder, urinary bladder neoplasm, urinary system disorder | Recruiting | Not stated | 2026-04-30 | NCT05002556 | |
| Cold Agglutinin Disease Real World Evidence Registry | Hemic and Lymphatic Diseases, anemia, autoimmune disease, autoimmune hemolytic anemia, hematologic disorder, hemolytic anemia, immune system disorder | Active, not recruiting | Not stated | 2026-04-22 | NCT05791708 | |
| AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms | Embolism and Thrombosis, Hemic and Lymphatic Diseases, Hemorrhage, Myeloproliferative Disorders, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Thromboembolism, acquired polycythemia vera, blood coagulation disease, blood platelet disease, bone marrow disorder, bone marrow neoplasm, cardiovascular disorder, cellular phase chronic idiopathic myelofibrosis, essential thrombocythemia, hematologic disorder, hematopoietic and lymphoid system neoplasm, hemorrhagic disease, neoplasm, primary myelofibrosis, thrombocytosis disease, vascular disorder, venous thromboembolism | Recruiting | Phase 3 | 2026-03-20 | NCT05198960 | |
| A Study of Elritercept Alone or Together With Ruxolitinib in Adults With Myelofibrosis | Cytopenia, Hemic and Lymphatic Diseases, Myeloproliferative Disorders, anemia, blood platelet disease, bone marrow disorder, hematologic disorder, primary myelofibrosis, thrombocytopenia | Recruiting | Phase 2 | 2026-02-05 | NCT05037760 | |
| STop and Restart Acalabrutinib In fRail Patients With Previously Untreated Chronic Lymphocytic Leukemia | Untreated Chronic Lymphocytic Leukemia | Active, not recruiting | Phase 2 | 2025-12-03 | NCT04963946 | |
| Preemptive Therapy for High Risk Chronic Lymphoid Leukemia Stage A | Hemic and Lymphatic Diseases, Leukemia, B-Cell, Neoplasms by Histologic Type, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Phase 2 | 2025-11-26 | NCT03766763 | |
| Incidence and Risk Factors for Post-Anesthetic Morphine Titration in Recovery Room After Hip and Knee Arthroplasties | Arthropathy of Hip; Arthropathy of Knee | Active, not recruiting | Not stated | 2025-02-18 | NCT06832995 |